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1. Introduction 
The intermediate lobe of the pituitary of many 
species synthesizes adrenocorticotropin (ACTH), 
/3-lipotropin @LPH), a-melanotropin (a-MSH) and 
Pendorphin (&END). Biosynthesis studies have shown 
that these peptides are cleaved from a glycosylated 
common prohormone, pro-opiocortin (M, 32 000, 
see fig.1) [l-4]. The primary structure of bovine 
pro-opiocortin has been derived from the nucleotide 
sequence of the cloned cDNA of the molecule [5], 
and the amino acid sequence revealed pairs of basic 
amino acids separating each of the peptides to be 
cleaved (see fig.1) similar to other prohormones [6]. 
Therefore, it has been proposed that processing of 
pro-opiocortin requires a trypsin-like enzyme to 
cleave at the basic amino residues, followed by the 
action of a carboxypeptidase B-like enzyme to 
remove the basic amino acid from the C-terminus. 
Studies indicate that the processing occurs intragranu- 
larly [7,8] and therefore such enzymes are likely to 
be localized within the secretory granules. 
We had showed the presence of a pro-opiocortin 
converting activity, that cleaves specifically at pairs of 
basic amino acids, in rat pituitary neurointermediate 
.-pmlIcLIpl[ ‘I-LPI-I ] (EndorDhlnl 
Fig.1. Structure of pro-opiocortin showing the arrangement 
of the different products in the molecule and the location of 
the basic amino acid pairs, as found in the bovine sequence (51. 
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lobe secretory granules [9]. In [9], characterization 
of the activity using different protease inhibitors, sug- 
gested that the enzyme was a unique, acid-thiol- 
arginyl protease. Here we have assayed for this pro- 
opiocortin converting activity in the intermediate 
lobe and the neural lobe separately. We show that 
purified secretory granules from both rat intermedi- 
ate and neural lobes contain a pro-opiocortin convert- 
ing activity that is specific for pairs of basic amino 
acids, similar to that reported for neurointermediate 
lobe granules [9]. However, the converting activity in 
the 2 lobes differed in their preferences for the paired 
basic amino acid cleavage sites in the pro-opiocortin 
molecule. 
2. Materials and methods 
2.1. Animals 
Female rats (Osborne-Mendel strain) (200-250 g 
body wt) were obtained from the National Institutes 
of Health (Bethesda MD). Adult toads (Xenopus 
Levis), 40-70 g were purchased from NASCO Bio- 
logical Supplies (Fort Atkinson WI) and maintained 
in a black plastic aquarium at 22*C with constant 
light for 15-21 days before use. 
2.2. Preparation of labeled toad pro-opiocortin 
(A CTHjendorphin precursor) 
Toad neurointermediate lobes were preincubated 
at 22°C in amphibian ringer [9] for 1 h and then 
‘pulse’ incubated for 1.5 h in amphibian ringer con- 
taining 19.5 /.IM [3H]phenylalanine (New England 
Nuclear Corp. (Boston MA), spec. act. 13.7 Ci/mmol). 
After the pulse, the lobes were homogenized in 0.1 M 
HCl and the proteins precipitated with 10% trichloro- 
acetic acid. Labeled pro-opiocortin was purified by 
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acid gel electrophoresis, omitting urea in the gel [9]. 
Following electrophoresis of the trichloroacetic acid- 
precipitated proteins, the gel was sliced and each gel 
slice was eluted with 0.02 M HCl/0.025 mg bovine 
serum albumin/ml. The eluant from the gel slice(s) 
containing the pro-opiocortin was lyophilized for use 
as substrate. The labeled pro-opiocortin substrate was 
80-85% pure as determined by immunoprecipitation 
with adrenocorticotropin (ACTH) and endorphin 
antisera. 
2.3. Preparation of secretory granules from the 
intermediate and neural lobes 
Neurolntermediate lobes were removed from 
50 rats and each neural obe was separated from the 
intermediate lobe by microdissection. The intermedi- 
ate and the neural obes were then homogenized sepa- 
rately in 2 ml 0.25 M sucrose/l0 mM Tris-HCl, pH 7.4 
at 0°C using a Potter-Elvehjem-type homogenizer. 
The homogenate was then subjected to differential 
centrifugation as in [9,10]. Five different fractions 
(PI-P, and S) were generated by this procedure. 
Each fraction was assayed for a-MSH in the inter- 
mediate lobe [ 111 and arginine-vasopressin (AVP) in 
the neural obe [lo], /I-glucuronidase (lysosomal 
marker) [lo] and monoamine oxidase (MAO, mito- 
chondrial marker) [ 121. The PI, fractions from the 
intermediate and neural obes were found to have the 
highest content of a-MSH (77%) and AVP (35%), 
respectively, suggesting that they are granule-enriched 
fractions. The P,, fraction from the 2 lobes was 
taken for further purification by discontinuous 
sucrose density gradient centrifugation as in [lo]. 
After centrifugation, the centrifuge tube was pierced 
and fifteen 25 drop fractions were collected from the 
sucrose density gradient. Each fraction was analyzed 
for (u-MSH or AVP, fl-glucuronidase and MAO. The 
analyses indicated that fraction 6 contained highly 
purified secretory granules (see fig.2) and it was taken 
for analysis of pro-opiocortin converting activity. 
2.4. Assay of pro-opiocortin converting activity in rat 
intermediate and neural lobe secretory granules 
The secretory granules from fraction 6 of the 
sucrose gradient for each of the lobes were osmoti- 
cally lysed and then adjusted to pH 5.0 with ammo- 
nium acetate buffer (final cont. 0.1 M). The labeled 
pro-opiocortin substrate was dissolved in 0.1 M 
ammonium acetate (pH 5) buffer. The secretory gran- 
ule lysate containing 20-25 pg protein was then 
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incubated together with labeled pro-opiocortin 
(-5000 cpm) in 200 pl total vol. for 5 h at 37°C. In 
assays done at pH 7.4, granules were lysed and incu- 
bations carried out using 10 mM Tris-HCl buffer. At 
the end of the Incubation the reaction was stopped 
by the addition of HCl to 0.2 M HCl final cont. Ali- 
quots of the incubation mixture were taken for analy 
sis by acid-urea gel electrophoresis. For the identifi- 
cation of the processed products, aliquots of the 
incubation mixture were quantitatively immunopre- 
cipitated with excess ACTH or &endorph.in (RB 100) 
antisera. The ACTH antiserum used is specific for the 
N-terminus of ACTH, and crossreacts with pro-opio- 
cortin, ACTH1_a9, ACTHI_+, and (w-MSH but not 
ACTHr,_s+ The /I-endorphin antiserum used is spe- 
cific for the C-terminus of &LPH (beyond residue 77) 
and crossreacts with pro-opiocortin, fl-LPH and 
/I-endorphin but not aendorphin [ 131. The immuno- 
precipitates were analyzed by acid-urea gel electro- 
phoresis as in [3,9], except hat Staphylococcus 
aureus Cowan I cells (IgGsorb, The Enzyme Center 
Inc. (Boston MA)) was used to precipitate the anti- 
gen-antibody complexes. The N-terminal 16 000 Mr 
glycopeptide product was identified by Mr.-value and 
ability to bind concavalin A [ 141. The Mr of pro- 
cessed products were determined by SDS gel electro- 
phoresis [ 151. 
2.5. Inhibitor studies 
Proteolytic inhibitors, p-chloromercuribenzoate 
(PCMB), diisopropylfluorophosphate (DFP), and 
chloroquine were purchased from Sigma Chemicals 
Co. (St Louis MO). Leupeptin and pepstatin A were 
gifts from Drs W. Troll and Umezawa (New York 
NY). The concentration of the inhibitors is reported 
in the text. 
3. Results 
3 .l . Analysis of the purity of the secretory granules 
from intermediate and neural lobes 
The results of isolation of the intermediate and 
neural lobe secretory granules used in this study is 
shown in fig.2. In the intermediate lobe (fig2A), 
fraction 6 was determined to be the purest a-MSH 
containing granule fraction since it contained no 
mitochondrial MAO activity and had the least con- 
tamination with lysosomal &$curonidase activity 
(<0.5% of that present in the original intermediate 
lobe). In the neural lobe (fig.2B), fraction 6 was also 
Volume 137, number 1 FEBS LETTERS January 1982 
the purest of the 3 hormone (AVP) containing gran- 
ule fractions. This fraction contained no mitochon- 
drial MAO activity and had minimal contamination 
with lysosomal fl-glucuronidase activity (<0.8% of 
that present in the original neural lobe tissue). In 
both the intermediate and neural lobes, the MAO and 
/I-glucuronidase activities were maximally concen- 
trated in fraction 11. Thus the granules in fraction 6 
of the intermediate and neural lobe preparations were 
used to assay for the pro-opiocortin converting activity. 
4. Intermediate Lobe 
&+l a-MSH 
C 4 /3-GLUC 
W MAO 
B. Neural Lobe 
Dd AVP 
+ 4 /%GLUC 
o---o MAO 
A 
2 4 6 8 10 12 14 
FRACTION NUMBER 
Fig.2. Distributions of hormone (ar-MSH or AVP) and enzyme 
activities (MAO, monoamine oxidase;flGluc, fl-glucuronidase) 
in the PJfJ (granule) fraction of intermediate (A) and neural 
lobe (B) after sucrose densitygradient centrifugation (see 
methods). The data are expressed on the ordinate as a % of 
the total hormone content (or enzyme activity) in the PLLf 
fraction which was found in each gradient fraction after den- 
sity gradient centrifugation (abscissa). 
3.2. Incubation of toad pro-opiocortin with inter- 
mediate lobe granule lysates 
[3H]Phenylalanine labeled pro-opiocortin was 
incubated with and without lysed secretory granules 
(SG) at pH 5 or pH 7.4 for 5 h at 37°C. Incubations 
with SG at pH 5 resulted in 83.3% conversion of pro- 
opiocortin while essentially no conversion was 
observed at pH 7.4 (not shown). Incubations in the 
absence of SG at pH 5 showed no conversion of the 
prohormone (flg3A), but in the presence of SG, sev- 
eral products were formed (fig.3). The toad pro-opio- 
cortin was cleaved to form a 21 OOOM, (21 kM,) 
ACTH, 2 forms of 13 000 M, (13 kM,) ACTH and 
(r-MSH as identified by immunoprecipitation with 
ACTH antiserum (fig.3A,B (0)). A 16 OOOM, glyco- 
peptide cleavage product (16 kM, GP) was detected 
and identitled as the N-terminal glycopeptide of pro- 
opiocortin by its size, binding to con A and lack of 
immunoprecipitation by ACTH or endorphin antisera 
(fig3A). Cleavage products corresponding to @-LPH 
and 2 forms of fl-endorphin were detected by immu- 
noprecipitation with flendorphin antiserum (fig.3A,B 
(0)). One of the &endorphin-like peptides @-END) 
migrated with a mobility close to that of the P-endor- 
phin standard, while the other @-ELP) migrated at 
slice 45. The fl-endorphin immunoprecipitation data 
(flg3B (0)) also revealed a large fl-endorphin related 
product (21 kM,). This molecule was found to have 
the ACTH sequence as well, as determined by sequen- 
tial immunoprecipitation with ACTH and endorphin 
antisera, i.e., immunoprecipitation with endorphin 
antiserum after immunoprecipitation with ACTH 
antiserum resulted in the absence of the 21 kM, 
endorphin-related peak. It is therefore referred to as 
the ACTH/&LPH product. This product accounts for 
35-45% of the radioactivity in the 21 kMr ACTH 
immunoprecipitated peak (fig.3B (0)). 
3.3. Incubation of toad pro-opiocortin with rat neural 
lobe granule lysates 
Incubation of [3H]phenylalanine labeled pro-opio- 
cortin for 5 h at 37’C with lysed neurosecretory gran- 
ules (NSG, fraction 6) at pH 5 .O resulted in 81.9% 
conversion of the substrate, but there was essentially 
no processing when the incubation was at pH 7.4 (not 
shown). Incubations at pH 5.0 for 5 h in the absence 
of NSG showed no conversion of pro-opiocortin but 
in the presence of NSG, several products were formed 
(tig.4). Two products were identified by immunopre- 
cipitation, with ACTH antiserum (figAB (0)) as a large 
59 
Volume 137, number 1 FEBS LETTERS January 1982 
form of ACTH havingiVr - 13 000 (13 kM,) and products formed were shown to be immunoprecipi- 
a-MSH (slice 53). Another product was identified as tated by /3-endorphin a tiserum (figAB (0)). One of 
the 16 OOOM, N-terminal glycopeptide (16 kMr CP) them was identified as /3-LPH on the basis of its size 
of pro-opiocortin by its binding to con A,Mr-value (fig.lA,B (0)). An o th er migrated at slice 45 (fig.4B 
and lack of immunoprecipitation byeither ACTH or (o)), and is referred to as a fl-endorphhr-like p ptide 
endorphin antisera (compare figAA,B). Three of the @-ELP). A 21 000 M, (2 1 kM,) anti$endorphin 
6- 
8- 
6- 
SLICE NUMBER SLICE NUMBER 
Fig.3. Conversion of [sH]phenylalanine labeled proopiocor- Fig.4. Conversion of [“H]phenylalanine labeled pro-opiocor- 
tin, at pH 5.0, by lysed rat intermediate lobe secretory gran- tin, at pH 5.0, by lysed rat neural lobe secretory granules 
ules (SG). (A) Acid-urea gel profiles of labeled proteins and (NSG). (A) Acid-urea gel profiles of labeled proteins and 
peptides following a 5 h incubation (pH 5.0, 37°C) of the peptides following a 5 h incubation (pH 5.0,37”C) of the 
[sH]proopiocortin in the absence (o---o) and presence [aH]pro-opiocortin substrate in the absence (o---o) and 
(o-o) of lysed secretory granules. Note that conversion of presence (e-0) of lysed secretory granules. Note that con- 
the pro-opiocortin to peptide products occurs only in the version of the proopiocortin to peptide products occurs only 
presence of secretory granule lysate. The identity of the in the presence of secretory granule lysate. The identity of 
products cleaved from pro-opiocortin is indicated above the the peptide derived from pro-opiocortin is indicated above the 
peak. (B) Immunological identification of peptide products peak. (B) Immunological identification of peptide products 
seen in (A). An equal aliquot of the incubate as used for (A) seen in (A). An equal aliquot of the incubate as used in (A) 
was immunoprecipitated with ACTH (e-o) or p-endorphin immunoprecipitated with ACTH (o-e) or pendorphin 
antisera (o---o) followed by acid-urea gel electrophoresis. antisera (o---o), followed by electrophoresis on acid-urea 
IPT, immunoprecipitate. Each profile shown in fig.3A,B is gels. IPT, immunoprecipitate. Each profile shown in figAA,B 
representative of 3 and 2 expt, respectively. The percentage is representative of 3 and 2 expt, respectively. The percent- 
of total cpm in each identified peak varied <15% between age of total cpm in each identified peak varied <lS% between 
the duplicate (triplicate) experiments. the duplicate (triplicate) experiments. 
21 K ACTH 16K 
GP 
ACTH:LPH. 1 
10 
- I-) NSG 
- I+) NSG 
6 
21 K ACTH 
:TH:I 
: I+) NSG 
- ACTH IPl 
- END IPT 
r 
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immunoprecipitated product was also detected (figAB 
(0)). This molecule is referred to as ACTH/&LPH 
since it is immunoprecipitated by both ACTH and 
endorphin antisera. The presence of both the ACTH 
and endorphin antigenic determinants on this mole- 
cule was further confirmed by sequential immuno- 
precipitation. All of the radioactivity immunoprecipi- 
tated by the Pendorphin antiserum in the 21 kM, 
peak appears to be due to the ACTHIP-LPH product, 
and accounts for 80% of the total ACTH immuno- 
precipitable activity in the peak. 
3.4. Characterization of the pro-opiocortin converting 
activity in intermediate and neural lobe secretory 
granules 
A comparison of the nature of the pro-opiocortin 
converting activity in the rat intermediate and neural 
lobe secretory granules was conducted using different 
protease inhibitors. Table 1 shows that PCMB, a thiol 
protease inhibitor and leupeptin, an arginyl protease 
inhibitor [ 161 were effective in inhibiting the con- 
verting activity in both lobes. Pepstatin A was also 
effective in inhibiting the converting activity in the 
intermediate and neural obes. Chloroquine, an inhibi- 
tor of cathepsin B [ 171 and DFP, an inhibitor of ser- 
ine proteases were without effect on the converting 
activity of either lobe. 
4. Discussion 
Here, we have demonstrated the presence of a pro- 
opiocortin converting activity in the secretory gran- 
ules of both intermediate and neural obes, that is 
similar to that reported for the total neurointermedi- 
ate lobe [9]. The products formed in both lobes, 
suggests hat cleavages occurred at the paired basic 
ammo acid residues (see fig.1, [9]). These products did 
Table 1 
Effect of proteolytic inhibitors on proopiocortin conversion 
by intermediate and neural lobe secretory granules 
Inhibitor % Inhibitiona 
Intermediate lobe Neural lobe 
DFP (1 mM) 8.0 ?: 3.8 (2) 12.0 f 5.2 (2) 
PCMB (1 mM) 95.5 f 4.5 (3) 104.0 f 7.0 (3) 
Leupeptin (2 mM) 60.5 * 3.5 (2) 63.5 + 3.0 (2) 
Chloroquine (100 PM) 4.0 f 2.0 (2) 9.0 f 1.7 (2) 
Pepstatin A (1 mM) 93.0 (I) 88.2 (1) 
a Mean f standard deviation; no. expt is shown in parenthesis 
not undergo further degradation i the presence of 
granule lysate for 218 h (unpublished). The two lobes, 
however, showed some difference in the products 
formed. The intermediate lobe granule lysate appears 
to preferentially cleave pro-opiocortin at the paired 
basic ammo acid residues between ACTH and /3-LPH 
(see fig.1) yielding predominantly 21 kM, ACTH 
(16 Wr glycopeptide t ACTH) and p-LPH (fig.3). In 
contrast, the neural obe granule lysate appears to 
cleave primarily at the paired basic amino acid resi- 
dues between the 16 kiWr glycopeptide and ACTH 
(see fig.l), yielding ACTHIP-LPH and the N-terminal 
16 k&f, glycopeptide as major products (fig.4). Note 
the larger 16 WM, glycopeptide and 21 kM, anti@ 
endorphin immunoprecipitated peaks in the neural 
lobe incubate as compared to that of the intermediate 
lobe (cf. fig.3,4). The second ifference is that fewer 
processed products were formed by the granule 
lysates of the neural obe versus intermediate lobe 
(fig.3,4). While pro-opiocortin incubated with inter- 
mediate lobe granule lysate was processed to 2 forms 
of 13 kMr ACTH, 2 forms of flendorphin (including 
one that co-migrated close to synthetic @ndorphin), 
/3-LPH and (u-MSH; neural obe granule lysates cleaved 
the substrate to primarily one form of 13 MM, ACTH 
and flendorphin @-ELP), /3-LPH and cu-MSH. Forma- 
tion of the flendorphin product that co-migrated 
with synthetic flh-endorphin occurred only with the 
intermediate lobe granule lysate (fig.3) but not with 
the neural obe (fig.4). All of the cleavage products 
formed by the rat intermediate lobe granule lysates 
are similar in electrophoretic mobility, on acid-urea 
gels, to those synthesized by the toad intermediate 
lobe [3,18]. However, the 21 k&f, ACTH@-LPH mol- 
ecule, the major product cleaved by the rat neural 
lobe granule lysate is not a significant product in the 
toad intermediate lobe [3 ,181. 
While there are subtle differences in the specificity 
of the cleavage of pro-opiocortin by the granules 
from the intermediate and neural obes, a comparison 
of the pH optima and inhibitor profiles of the activi- 
ties suggest that the 2 enzymes are very similar. The 
2 activities are greater at pH 5.0 than pH 7.4, suggest- 
ing that they are acid proteases. The inhibitor 
studies (table 1) show that the converting activities 
from both lobes are inhibited by the same agents, i.e., 
PCMB (a thiol protease inhibitor), leupeptin (an 
arginyl protease inhibitor [ 161) and pepstatin A (an 
inhibitor that acts by formation of hydrophobic and 
hydrogen bonds with the enzyme [ 19,201). DFP, a 
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serine protease inhibitor and chloroquine, acathep- 
sin B inhibitor [ 171 were without effect on the con- 
verting activities in either lobe. This inhibitor profile 
suggests hat the pro-opiocortin converting activities 
in the intermediate and neural obe granules are both 
due to an acid-thiol-arginyl protesase, distinct from 
cathepsin B, as suggested from our studies on the 
rat neurointermediate lobe [9]. The inhibition by 
pepstatin A suggests hat the converting enzymes 
may have secondary hydrophobic and/or hydrogen- 
bonding sites that are involved in enzyme-substrate 
interaction [19,201. Inhibition of converting activity 
by leupeptin, a hydrophobic molecule, occurs only at 
concentrations higher than that necessary to block 
trypsin activity [ 191. This raises the possibility that 
the inhibition by leupeptin may not be due to specific 
binding at the active site as with trypsin, but rather 
may be due to a secondary effect, e.g., by binding to 
hydrophobic sites on the enzyme. The characteristics of 
the pro-opiocortin converting activity in the interme- 
diate and posterior pituitary are also similar to the con- 
verting activities reported for pro-insulin, pro-glucagon 
and pro-somatostatin in the pancreatic islet granules 
of anglerfish [21,22]. Thus, there may exist a family 
of prohormone converting activities that are very sim- 
ilar in nature but differ slightly in their specificities. 
In conclusion, we have shown that the intermediate 
lobe and neural obe granules both contain an acid- 
thiol-arginyl protease that cleaves at paired basic 
amino acid residues, yet show subtle differential pref- 
erences for the paired basic amino acid cleavage sites 
of pro-opiocortin. This difference is perhaps not sur- 
prising since pro-opiocortin is not a natural substrate 
in the neural obe. The converting activity in the neu- 
ral lobe granules i  probably tailored to cleave the 
prohormones for vasopressin and oxytocin synthe- 
sized in the hypothalamo-neurohypophysial ystem 
[23-2.51. It is possible that such subtle differences in 
the specificity of the cleavage process of the convert- 
ing activities in the 2 lobes may be dictated by the 
conformation of the enzymes as well as the substrate. 
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